CA3235692A1 - Modified forms of ambroxol for therapeutic use - Google Patents
Modified forms of ambroxol for therapeutic use Download PDFInfo
- Publication number
- CA3235692A1 CA3235692A1 CA3235692A CA3235692A CA3235692A1 CA 3235692 A1 CA3235692 A1 CA 3235692A1 CA 3235692 A CA3235692 A CA 3235692A CA 3235692 A CA3235692 A CA 3235692A CA 3235692 A1 CA3235692 A1 CA 3235692A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- disease
- ambroxol
- subject
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/70—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272743P | 2021-10-28 | 2021-10-28 | |
| US63/272,743 | 2021-10-28 | ||
| PCT/US2022/078779 WO2023076997A1 (en) | 2021-10-28 | 2022-10-27 | Modified forms of ambroxol for therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3235692A1 true CA3235692A1 (en) | 2023-05-04 |
Family
ID=84364209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235692A Pending CA3235692A1 (en) | 2021-10-28 | 2022-10-27 | Modified forms of ambroxol for therapeutic use |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250235413A1 (enExample) |
| EP (1) | EP4423041A1 (enExample) |
| JP (1) | JP2024540241A (enExample) |
| KR (1) | KR20240095271A (enExample) |
| CN (1) | CN118660866A (enExample) |
| CA (1) | CA3235692A1 (enExample) |
| WO (1) | WO2023076997A1 (enExample) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5354566A (en) | 1993-06-02 | 1994-10-11 | Kraft General Foods, Inc. | Preparation of yeast-leavened dough crusts |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| IL160539A0 (en) | 2001-09-04 | 2004-07-25 | Boehringer Ingelheim Int | Anti-influenzal agents |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| DE10332487A1 (de) | 2003-07-16 | 2005-02-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| CA3055311A1 (en) * | 2017-02-07 | 2018-08-16 | Stc.Unm | Isotope enhanced ambroxol for long lasting autophagy induction |
| CN114907221A (zh) * | 2021-02-06 | 2022-08-16 | 华创合成制药股份有限公司 | 一种氘代氨溴索衍生物及其制备和用途 |
-
2022
- 2022-10-27 CN CN202280079899.3A patent/CN118660866A/zh active Pending
- 2022-10-27 EP EP22813844.2A patent/EP4423041A1/en active Pending
- 2022-10-27 WO PCT/US2022/078779 patent/WO2023076997A1/en not_active Ceased
- 2022-10-27 JP JP2024525932A patent/JP2024540241A/ja active Pending
- 2022-10-27 US US18/705,344 patent/US20250235413A1/en active Pending
- 2022-10-27 KR KR1020247017158A patent/KR20240095271A/ko active Pending
- 2022-10-27 CA CA3235692A patent/CA3235692A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023076997A1 (en) | 2023-05-04 |
| JP2024540241A (ja) | 2024-10-31 |
| EP4423041A1 (en) | 2024-09-04 |
| US20250235413A1 (en) | 2025-07-24 |
| CN118660866A (zh) | 2024-09-17 |
| KR20240095271A (ko) | 2024-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3964503B1 (en) | A crystalline form of a magl inhibitor | |
| JP6395838B2 (ja) | 神経疾患の処置のためのトラセミド及びバクロフェンを含む組成物 | |
| EP2680836B1 (en) | New compositions for treating neurological disorders | |
| TWI692465B (zh) | 酚系trpv1促效劑之前藥 | |
| US10765646B2 (en) | Methods of treating developmental encephalopathies | |
| JP2022105159A (ja) | 統合失調症を治療するための2-((1-(2(4-フルオロフェニル)-2-オキソエチル)ピペリジン-4-イル)メチル)イソインドリン-1-オン | |
| JP2009537565A (ja) | R(+)およびs(−)プラミペキソール組成とそれを利用する方法 | |
| EP1988898A2 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| WO2012135623A1 (en) | Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline | |
| US20160015684A1 (en) | Compositions comprising bioreversible derivatives of hydroxy n- substituted-2-aminotetralins, dosage forms, and related methods | |
| US11583543B2 (en) | Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity | |
| EP2968227B1 (en) | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | |
| US9475836B2 (en) | Protopanoxadiol derivative, preparation method thereof and application thereof | |
| US20250235413A1 (en) | Modified forms of ambroxol for therapeutic use | |
| JP2015172059A (ja) | トリプル再取込み阻害剤及びそれらの使用方法 | |
| US20250011277A1 (en) | Modified forms of ambroxol for therapeutic use | |
| JP2025530455A (ja) | うつ病を治療又は緩和するための4-tmapの使用 | |
| JP2024533182A (ja) | 酸性pHで増強された効力を有するN-メチル-D-アスパラギン酸受容体のGluN2Bサブユニット選択的アンタゴニスト | |
| CN102516101A (zh) | 1r,2s-甲氧胺在制备治疗大便失禁和其他相关疾病的药物中的应用 | |
| CN114053256B (zh) | 一种预防和治疗精神障碍性疾病的化合物及其应用 | |
| KR20250047213A (ko) | 질소 함유 헤테로고리 화합물의 다형체 및 그의 용도 | |
| HK40069310B (en) | A crystalline form of a magl inhibitor | |
| HK40009165B (en) | A crystalline form of a magl inhibitor | |
| HK40009165A (en) | A crystalline form of a magl inhibitor | |
| HK1190607A (en) | New compositions for treating neurological disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241018 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241018 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241018 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241104 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251017 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251021 |